We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Wall Street analysts forecast that Revvity (RVTY - Free Report) will report quarterly earnings of $1.14 per share in its upcoming release, pointing to a year-over-year decline of 10.9%. It is anticipated that revenues will amount to $699.98 million, exhibiting an increase of 2.3% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Revvity metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Net Sales- Life Sciences' reaching $338.39 million. The estimate indicates a change of +12.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Diagnostics' will reach $361.25 million. The estimate indicates a year-over-year change of -5.8%.
Analysts forecast 'Organic revenue growth - Diagnostics' to reach 0.2%. The estimate compares to the year-ago value of 5.0%.
Revvity shares have witnessed a change of +13% in the past month, in contrast to the Zacks S&P 500 composite's +1.1% move. With a Zacks Rank #4 (Sell), RVTY is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Revvity (RVTY) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Wall Street analysts forecast that Revvity (RVTY - Free Report) will report quarterly earnings of $1.14 per share in its upcoming release, pointing to a year-over-year decline of 10.9%. It is anticipated that revenues will amount to $699.98 million, exhibiting an increase of 2.3% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Revvity metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Net Sales- Life Sciences' reaching $338.39 million. The estimate indicates a change of +12.5% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Diagnostics' will reach $361.25 million. The estimate indicates a year-over-year change of -5.8%.
Analysts forecast 'Organic revenue growth - Diagnostics' to reach 0.2%. The estimate compares to the year-ago value of 5.0%.
View all Key Company Metrics for Revvity here>>>Revvity shares have witnessed a change of +13% in the past month, in contrast to the Zacks S&P 500 composite's +1.1% move. With a Zacks Rank #4 (Sell), RVTY is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .